SIRT1 and familial pancreatic carcinoma: Notably, treatment with the SIRT1 inhibitor EX527 reduced the proliferation of pancreatic cancer cells and enhanced their sensitivity to gemcitabine in vitro, but no apparent effects on EMT were seen.